biomedicina slovenica

pr=Chatzidionysiou : 22

  1. Courvoisier Delphine S.; Chatzidionysiou Katarina; Mongin Denis; Lauper Kim; Mariette Xavier; Morel Jacques; Gottenberg Jacques-Eric; Bergstra Sytske Anne; Pombo-Suarez Manuel; Rotar Žiga
    The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents
    2020 ►
  2. Chatzidionysiou Katerina; Lukina Galina; Gabay Cem; Hetland Merete L.; Hauge Ellen Margrethe; Pavelka Karel; Nordström Dan C.; Canhao Helena; Tomšič Matija; Rotar Žiga
    Smoking and response to rituximab in rheumatoid arthritis
    2018 ►
  3. Chatzidionysiou Katerina; Lie Elisabeth; Lukina Galina; Hetland Merete L.; Hauge Ellen Margrethe; Pavelka Karel; Gabay Cem; Scherer Almut; Tomšič Matija; Rotar Žiga
    Rituximab retreatment in rheumatoid arthritis in a real-life cohort
    2017 ►
  4. Chatzidionysiou Katerina; Lie Elisabeth; Nasonov Evgen; Lukina Galina; Lund Hetland Merete; Tarp Ulrik; Ancuta Ioan; Pavelka Karel; Nordström Dan C.; Tomšič Matija
    Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort
    2016 ►
  5. Gabay Cem; Riek Myriam; Lund Hetland Merete; Hauge Ellen Margrethe; Pavelka Karel; Tomšič Matija; Canhao Helena; Chatzidionysiou Katerina; Lukina Galina; Nordström Dan C.
    Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis
    2016 ►
  6. Walker Ulrich A; Jaeger Veronika K.; Chatzidionysiou Katerina; Hetland Merete L.; Hauge Ellen Margrethe; Pavelka Karel; Nordström Dan C.; Canhao Helena; Tomšič Matija; Van Vollenhoven Ronald F.; Gabay Cem
    Rituximab done
    2016 ►
  7. Chatzidionysiou Katerina; Lie Elisabeth; Nasonov Evgen; Lukina Galina; Hetland Merete L.; Hauge Ellen Margrethe; Pavelka Karel; Gabay Cem; Nordström Dan C.; Canhao Helena; Tomšič Matija
    Smoking and response to rituximab in anti-CCP positive and negative rheumatoid arthritis
    2015 ►
  8. Chatzidionysiou Katerina; Lie Elisabeth; Nasonov Evgen; Lukina Galina; Lund Hetland Merete; Hauge Ellen Margrethe; Pavelka Karel; Gabay Cem; Nordström Dan C.; Tomšič Matija
    Smoking and response to Rituximab in Anti-CCP positive and negative rheumatoid arthritis - results from an International European Collaboration
    2014 ►
  9. Walker Ulrich A; Jaeger Veronika K.; Chatzidionysiou Katerina; Lund Hetland Merete; Hauge Ellen Margrethe; Pavelka Karel; Nordström Dan C.; Canhao Helena; Tomšič Matija; Van Vollenhoven Ronald F.
    Rituximab Done! What's Next in RA?
    2014 ►
  10. Chatzidionysiou Katerina; Lie Elisabeth; Nasonov Evgen; Pavelka Karel; Tomšič Matija
    Fixed versus on-flare retreatment with rituximab in RA - results from the cererra collaboration
    2014 ►
  11. Chatzidionysiou Katerina; Lie Elisabeth; Nasonov Evgen; Tomšič Matija
    Effectiveness of repeated courses of Rituximab in RA - results from the cererra collaboration
    2013 ►
  12. Chatzidionysiou Katerina; Lie Elisabeth; Nasonov Evgen; Tomšič Matija
    Fixed versus on-flare retreatment with Rituximab In RA-results from the cererra collaboration
    2013 ►
  13. Chatzidionysiou K; Lie E; Nasonov E; Tomšič M
    Efficacy of different doses of rituximab for the treatment or RA: data from CERERRA colaboration
    2012 ►
  14. Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Lund-Hetland M; Trap U; Gabay C; van Riel P; Nordstroem D; Tomšič M
    Retreatment with Rituximab yields better clinical outcomes, especially when it is given at fixed interval: data from the Cererra collaboration
    2011 ►
  15. Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Lund-Hetland M; Tarp U; Gabay C; van Riel P; Nordstroem D; Tomšič M
    Seropositivity, and in particular ACPA positivity is a strong predictor of response to treatment with Rituximab: pooled data from 10 European registries
    2011 ►
  16. Gabay C; Chatzidionysiou K; Nasonov E; Lukina G; Hetland ML; Tarp U; van Riel PL; Nordstrom D; Gomez-Reino J; Tomšič M
    Effectiveness of different DMARD co-therapies in Rituximab - treated rheumatoid arthritis (RA) patients - results of a one-year follow up study from Cerrera collaboration
    2010 ►
  17. Chatzidionysiou K; van Vollenhoven RF; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PLCM; Nordsroem DC; Tomšič M
    Efficacy of Rituximab retreatment in clinical practice: data from the Cererra collaboration
    2010 ►
  18. van Vollenhoven RF; Chatzidionysiou K; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PPLC; Nordstroem DC; Tomšič M
    Characterisation of RA patients not requiring retreatment with Rituximab within 12 months after the first course - a Cererra study
    2010 ►
  19. Chatzidionysiou Katerina; Lie Elisabeth; Nasonov Evgeny; Lukina Galina; Hetland Merete Lund; Tarp Ulrik; van Riel Piet LCM; Nordstrom Dan C; Gomez-Reino Juan; Tomšič Matija
    Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration
    2012 ►
  20. Chatzidionysiou Katerina; Lie Elisabeth; Nasonov Evgeny; Tomšič Matija
    Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries
    2011 ►
  21. van Vollenhoven Ronald; Chatzidionysiou K; Nasonov E; Tomšič M
    Six-month results from the collaborative European registries for rituximab in rheumatoid arthritis (CERERRA). Efficacy of rituximab is highest in RF-positive patients and in those who failed at most one prior anti-TNF
    2009 ►
  22. van Vollenhoven RF; Chatzidionysiou K; Gabay C; Tomšič M
    Rheumatoid factor predicts response to rituximab in a European registry-based cohort: 6-month results from the collaborative European registries for rituximab in rheumatoid arthritis (CERERRA)
    2009 ►

New search      Comments      Top of page Institute for Biostatistics and Medical Informatics